Aurora Oncology, Inc.
Aurora Oncology develops targeted biologics to satisfy the unmet need of improved efficacy and safety of bladder cancer therapy.
Aurora Oncology is focused on the development and commercialization of unique biologics for the treatment of superficial bladder cancer. DAB389EGF and Nano-EGFR work by targeting specific receptors on the surface of cancer cells. Nano-EGFR also allows for imaging of bladder cancer in the patient resulting in the potential for targeted therapy. Both of these products are poised to enter clinical development.